ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / RNAC / dividends
PRQR (54) AKBA (57) KRRO (44) NATR (68) ⌘ Pro Terminal →

Cartesian Therapeutics Inc. (RNAC) Dividend Safety Gauge & 10-Year DRIP Compounder

$6.49 -3.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.43

Cartesian Therapeutics Inc. (RNAC) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $204.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RNAC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RNAC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Cartesian Therapeutics Inc. (NASDAQ: RNAC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $6.49 (-3.85% 1D, market cap $204.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RNAC ranks #809 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RNAC compare to PRQR and AKBA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RNAC carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PRQR (ProQR Therapeutics N.V.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $203.2M) and AKBA (Akebia Therapeutics Inc.) posts a D+ grade (57/100 RQD, P/E N/A, ROIC 85.0%, cap $205.7M). Among the 5-stock peer group, NATR leads on earnings multiple (11.1x) while AKBA leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RNAC?
▼

Per RNAC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001453687), Cartesian Therapeutics Inc. generated $400.0K in revenue (-99.0% YoY), -$130.3M in net income, and -$79.4M in free cash flow against $296.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.43 (-0.88%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (3)Whales (11)SEC (3)Macro (13)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.2% Base Target
$12 Bull$6 Base$4 Bear
📬 FREE RNAC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RNAC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY RNAC SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (42% of score)

FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 39.7 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (35% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$6.99-13% Next Q
Q2 (-2Q)
36
Grade E$6.08+3.3% Next Q
Q3 (-1Q)
34
Grade E$6.28+3.3% Next Q
Current
31
Grade E$6.49-9.4% Hist 90D α
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RNAC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RNAC currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.66) and Max Pain ($6.81) forces dealer call-delta covering toward $11.55.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RNAC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RNAC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RNAC)

  • ✓Walkthrough of RNAC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RNAC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.35%📐 HORIZONTAL RANGE
2026-11-02O $6.49H $6.68L $6.20C $6.49VOL 40.6K
RES: $10.75SUP: $5.79SMA50: $7.66SMA200: $7.64
$11.37$9.85$8.33$6.82$5.30RES $10.75SUP $5.79$6.492026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RNAC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RNAC Butterfly Map → + Track RNAC →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RNAC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RNAC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RNAC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RNAC)

Health Care Rank #809 of 1016 ⚔️ PRQR vs RNAC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RNAC vs. PRQR, AKBA, KRRO, NATR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cartesian Therapeutics Inc. (RNAC) ranks #809 by composite RQD confidence (31/100, grade E) and #575 by equity capitalization ($204.2M). Within this direct 5-issuer industry benchmark cohort, NATR leads on earnings valuation at 11.1x trailing P/E, while AKBA leads on capital efficiency and profitability with 85.0% ROIC and 83.3% gross margin. NATR currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with RNAC at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RNAC ACTIVE
Cartesian Therapeutics Inc.
E 31/100 — — -35.0% -3.85% $204.2M Benchmark Subject
PRQR
ProQR Therapeutics N.V.
D+ 54/100 — — — -3.47% $203.2M /prqr-vs-rnac →
AKBA
Akebia Therapeutics Inc.
D+ 57/100 — 83.3% 85.0% -4.81% $205.7M /akba-vs-rnac →
KRRO
Korro Bio Inc.
D 44/100 — — -35.0% +0.81% $209.1M /krro-vs-rnac →
NATR
Nature's Sunshine Products Inc.
C+ 68/100 11.1x 72.4% 28.9% -0.24% $216.1M /natr-vs-rnac →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001453687

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cartesian Therapeutics Inc. (RNAC) reported GAAP revenue of $400.0K (-99.0% vs. FY2024 revenue of $38.3M , and -98.5% cumulative change since FY2023) , GAAP net income of -$130.3M, operating cash flow of -$73.9M, and free cash flow of -$79.4M (-142.3% YoY). On the balance sheet, RNAC closed FY2025 with $296.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $400.0K -$130.3M -$73.9M -$79.4M $296.4M $0
FY2024 (FY) 2024-12-31 $38.3M -$77.4M -$23.7M -$32.8M $435.0M —
FY2023 (FY) 2023-12-31 $26.0M -$219.7M -$51.2M -$51.2M — —

3. RNAC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RNAC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Cartesian Therapeutics Inc. (NASDAQ: RNAC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $6.49 (-3.85% 1D, market cap $204.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RNAC ranks #809 in composite RQD confidence.

How does RNAC compare to PRQR and AKBA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RNAC carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PRQR (ProQR Therapeutics N.V.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $203.2M) and AKBA (Akebia Therapeutics Inc.) posts a D+ grade (57/100 RQD, P/E N/A, ROIC 85.0%, cap $205.7M). Among the 5-stock peer group, NATR leads on earnings multiple (11.1x) while AKBA leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RNAC?

Per RNAC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001453687), Cartesian Therapeutics Inc. generated $400.0K in revenue (-99.0% YoY), -$130.3M in net income, and -$79.4M in free cash flow against $296.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RNAC trading relative to its 50-day, 200-day, and 52-week technical levels?

RNAC last traded at $6.49 (-3.85% on volume of 78,805 shares), positioning the stock -15.27% below its 50-day simple moving average ($7.66) and -15.05% below its 200-day simple moving average ($7.64). Across its 52-week range of $5.60 to $11.00, RNAC sits at the 16.5% percentile with a 14-day RSI of 39.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.68 to $7.30).

RNAC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does RNAC pay a dividend and is it safe?

Cartesian Therapeutics Inc. (RNAC) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: RNAC RQD Cockpit RNAC 12M Forecast RNAC Earnings & Move RNAC Dividends & DRIP RNAC Insiders & 13F RNAC Whale Options RNAC Profit Sankey RNAC News & Why
ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RNAC — Cartesian Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:41:07Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating assigns RNAC a score of 31 out of 100, a letter grade of E, and a verdict label of "Roarable Strong Sell — Forensic Risk / Avoid" (per the Roarable RQD rating). The five pillars break down as follows:

  • Fundamental Cash Engine: 2 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -35% and an FCF yield of 0%. For a prospective investor, this means the business is not currently generating returns on invested capital or free cash flow to support valuation on earnings or cash-flow grounds.
  • Whale 13F Flow: 11 / 20. This pillar captures institutional accumulation and options positioning. It is the strongest pillar in the rating, indicating some institutional interest, though the source data does not itemize the specific holdings behind this score.
  • Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. A low score signals limited insider conviction signals in the source data.
  • Macro Regime Fit: 13 / 20. Per the Roarable RQD rating, this pillar reflects a beta of 1.0 and sector sensitivity. The stock's beta of 1.0 implies market-level sensitivity, which is neutral rather than defensive or aggressive.
  • Forensic Balance Sheet: 2 / 20. Per the Roarable RQD rating, this pillar reflects an Altman Z-Score of 0.2, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. These forensic readings are weak and indicate elevated distress risk on the balance-sheet dimension.

Taken together, the low cash-engine and forensic scores drive the overall verdict. The upside case rests mainly on institutional flow rather than on operating fundamentals. A prospective investor weighing valuation tradeoffs should note that the source data contains no P/E, EPS, or EV/EBITDA figures, so the rating cannot be cross-checked against earnings-based valuation.

Business

Cartesian Therapeutics Inc. (RNAC) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile gives a market capitalization of $0.2B. Products sold, customer base, and revenue model are not available in source data. The financials show reported revenue of $0.4M for FY 2025, down from $38.3M for FY 2024 (per the SEC financials).

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.4M$-143.4M$-130.3MN/A$-79.4M$125.1M$0.0M
FY 2024$38.3M$-43.9M$-77.4MN/A$-32.8M$212.6MN/A
FY 2023$26.0M$-86.4M$-219.7MN/A$-51.2MN/AN/A

Per the SEC financials and market data, the company reported operating margin of -60%, net margin of -60%, and gross margin of 0%. ROIC is -35%, per the market data. The Roarable RQD rating records an Altman Z-Score of 0.2 and a Piotroski F-Score of 2/9 (per the Roarable RQD rating). Reported debt is $0.0M for FY 2025 and the Debt/Equity ratio is 0.5 (per the Roarable RQD rating and SEC financials). Cash fell from $212.6M in FY 2024 to $125.1M in FY 2025.

Recent Catalysts & News Wire Analysis

The news wire contains six items, each tagged with a YELLOW light and MARKET WIRE impact label, all related to RNAC:

  • A Yahoo Finance UK seasonal returns chart report.
  • A Moomoo options chain and news quote page.
  • A Seeking Alpha note headlined as maintaining a "Buy" rating on Descartes-08 MG data release and a CAR-T agreement, which is a named catalyst in the headline (per the news wire).
  • A TradingView earnings preview referencing a Q3'26 revenue estimate of 160.00K USD.
  • A TradingKey most-active-stocks report.
  • A Yahoo! Finance Canada seasonal returns chart for a different company, Evaxion A/S (EVAX), which is only tangentially related.

Risk watch items: the source summaries are largely generic and do not state the substance of the catalysts. The Butterfly Supply-Chain Graph reports no proprietary signals and no supply-chain links.

Open Questions

  • What are the specific terms and expected timing of the CAR-T agreement and Descartes-08 MG data release referenced in the news wire?
  • What drove the decline in reported revenue from $38.3M in FY 2024 to $0.4M in FY 2025, and what does the company's revenue base consist of?
  • How much of the cash balance of $125.1M is available to fund operations, given FY 2025 free cash flow of $-79.4M?
  • Who are the institutional holders behind the Whale 13F Flow score, and what is the direction and size of their positions?
  • What is the company's debt structure, given Debt/Equity of 0.5 alongside reported debt of $0.0M?

RNAC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cartesian Therapeutics Inc. (RNAC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RNAC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RNAC Bull vs. Bear Conversation Board — What's Your Call at $6.49?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RNAC 🐻 67% BEARISH CONVICTION
1. Pick Your Side on RNAC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $5.94 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is RNAC (E • RQD 31/100) a Buy at $6.75?

Welcome to the RNAC (Cartesian Therapeutics Inc.) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $5.47 (-19.0%)
Spot @ $6.75

Pump the brakes on RNAC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on RNAC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Cartesian Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $8.24 (+22.1%)
Spot @ $6.75

RNAC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on RNAC, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $6.75 (52-wk range $5.86 - $7.35), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%